Isha Shrestha, MD
Endocrinology, Diabetes & Metabolism · Everett, WANPI 1477965507
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $6,260 of the $7,134 with a category attached, or 87.8%. It is spread thinly across 30 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations.
Across 258 payments — averaging $27.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Amgen$997
- Novo Nordisk$551
- Sanofi-aventis U.S. LLC$440
- Tandem Diabetes Care, Inc.$412
- Boehringer Ingelheim$408
- plus $3K from 24 others
What the payments were for
- Travel & lodging$6489%
- Food & beverage$6,26088%
- Education$1672%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 18 | $1,632 |
| Amgen | 43 | $997 |
| Novo Nordisk | 27 | $551 |
| Sanofi-aventis U.S. LLC | 22 | $440 |
| Tandem Diabetes Care, Inc. | 14 | $412 |
| Boehringer Ingelheim | 17 | $408 |
| Mannkind Corporation | 12 | $392 |
| Lilly USA, LLC | 15 | $376 |
| Insulet Corporation | 15 | $333 |
| Corcept Therapeutics | 11 | $227 |
| Xeris Pharmaceuticals, Inc. | 9 | $201 |
| Radius Health, Inc. | 10 | $166 |
| Abbott | 2 | $143 |
| AstraZeneca(2 entities) | 7 | $113 |
| Novartis | 5 | $108 |
| Amarin Pharma, Inc. | 5 | $105 |
| Amryt Pharma Holdings Ltd | 3 | $80 |
| Recordati_rare_diseases_inc. | 3 | $78 |
| Bayer | 3 | $70 |
| Ascendis Pharma Endocrinology Inc | 2 | $43 |
| Johnson & Johnson | 2 | $39 |
| Kowa Pharmaceuticals America, Inc. | 2 | $35 |
| Lifescan, Inc. | 2 | $33 |
| Sequel Med Tech, LLC | 1 | $30 |
| Dexcom, Inc. | 1 | $24 |
| Halozyme Inc | 1 | $22 |
| Medicure Pharma Inc. | 1 | $22 |
| IBSA Pharma Inc. | 1 | $18 |
| Antares Pharma, Inc. | 1 | $17 |
| Companion Medical, Inc. | 3 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$1,068
- AFREZZA$140
- FREESTYLE LIBRE 3$126
- Tresiba$119
- TZIELD$109
- t:slim X2 Insulin Pump with Control-IQ$107
- JARDIANCE$105
- RYBELSUS$102
How this compares
$7,134 in reported general payments places this provider in the 80th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
See all endocrinology, diabetes & metabolism providers in Washington →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 342 | $521,881 |
| JardianceEmpagliflozin | 260 | $344,980 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 79 | $157,354 |
| TymlosAbaloparatide | 23 | $110,353 |
| TrulicityDulaglutide | 78 | $96,116 |
| MounjaroTirzepatide | 62 | $93,694 |
| RybelsusSemaglutide | 55 | $70,378 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 68 | $67,245 |
| FarxigaDapagliflozin Propanediol | 47 | $48,837 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 29 | $28,075 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 137 | $24,242 |
| Teriparatide | 12 | $23,961 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 23 | $21,498 |
| AfrezzaInsulin Regular, Human | 15 | $20,026 |
| Tresiba Flextouch U-100Insulin Degludec | 31 | $18,654 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Wegovy, Novolog | $551 | $611,547421 claims |
| Boehringer IngelheimJardiance | $408 | $344,980260 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Insulin Lispro | $376 | $199,564188 claims |
| Radius Health, Inc.Tymlos | $166 | $110,35323 claims |
| AstraZenecaFarxiga | $113 | $48,83747 claims |
| Mannkind CorporationAfrezza | $392 | $20,02615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 161 endocrinology, diabetes & metabolism providers in Washington.
Other endocrinology, diabetes & metabolism in Everett
- Shadi BadriehEverett$3K
- Sarena ToellnerEverett$2K
- Michael ShannonLacey$698K
- Lynn KohlmeierSpokane$518K
- Carol WyshamSpokane$512K
- Bruce WilsonRichland$352K
- Irl HirschSeattle$192K
- Biju KunhiramanYakima$118K
- Nicole EhrhardtSeattle$111K
- Kristina UtzschneiderSeattle$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.